Les mardis de le chimie durable MCD

HTE chemistry as catalyst for medicinal chemistry programs
Pablo Gabriel, société NOVARTIS

High-throughput experimentation (HTE) has emerged as a powerful tool in medicinal chemistry to accelerate drug discovery programs by rapidly screening and optimizing reaction conditions. In this communication, we will highlight the work of the SynTech Catalysis Laboratory, which specializes in HTE reaction condition screenings to remove synthetic bottlenecks throughout the medicinal chemistry portfolio within the Global Discovery Chemistry (GDC) organization of Novartis Biomedical Research. Our lab specializes in the optimization of metal-catalyzed reactions commonly encountered in drug discovery programs, including metal-catalyzed cross-coupling reactions, hydrogenations, carbonylations, and asymmetric hydrogenations.
Some more exploratory projects will also be discussed, from photochemistry, to the discovery of new ligands for copper catalysis.

Innovation as a key driver for more sustainable and controlled processes for API manufacturing

Raphaël Beltran, société SANOFI

The pharmaceutical industry faces multiple challenges: the push for complex disease treatments is driving the design of more intricate active pharmaceutical ingredients (APIs), while the landscape remains highly competitive and rapidly evolving, coupled with significant pricing pressures from patients and payers. Additionally, API synthesis processes must adhere to specific requirements, including a substantially reduced environmental footprint and cost efficiency all within compressed timelines to ensure timely clinical deliveries. To address these competing challenges, one strategic focus is the introduction of novel technologies such as High-Throughput Experimentation (HTE), biocatalysis, electro/photochemistry, kinetic characterization or even the recent emergence of Artificial Intelligence (AI). These technologies provide an opportunity to access molecules of high structural complexity with a reduced environmental footprint while achieving safety and robustness key requirements in industry. In this presentation, we wish to share with you the innovative strategy fostered by Sanofi to develop more sustainable, safe and robust processes toward the synthesis of complex APIs for the treatment of rare diseases.  

 Lien principal : https://rendez-vous.renater.fr/lobby/mardi_de_la_chimie_durable_3_fevier_510ff2-2b4d69-52fc59